| Literature DB >> 25809484 |
Ravikanth Nanduri1, Sahil Mahajan1, Ella Bhagyaraj1, Kanupriya Sethi1, Rashi Kalra1, Vemika Chandra1, Pawan Gupta2.
Abstract
The ability of the active form of vitamin D, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), to transcriptionally modulate Smads to inhibit Th17 differentiation and experimental autoimmune encephalomyelitis (EAE) has not been adequately studied. This study reports modulation of Smad signaling by the specific binding of the VDR along with its heterodimeric partner RXR to the negative vitamin D response element on the promoter of Smad7, which leads to Smad7 gene repression. The vitamin D receptor-mediated increase in Smad3 expression partially explains the IL10 augmentation seen in Th17 cells. Furthermore, the VDR axis also modulates non-Smad signaling by activating ERK during differentiation of Th17 cells, which inhibits the Th17-specific genes il17a, il17f, il22, and il23r. In vivo EAE experiments revealed that, 1,25(OH)2D3 suppression of EAE correlates with the Smad7 expression in the spleen and lymph nodes. Furthermore, Smad7 expression also correlates well with IL17 and IFNγ expression in CNS infiltered inflammatory T cells. We also observed similar gene repression of Smad7 in in vitro differentiated Th1 cells when cultured in presence of 1,25(OH)2D3. The above canonical and non-canonical pathways in part address the ability of 1,25(OH)2D3-VDR to inhibit EAE.Entities:
Keywords: Autoimmune Disease; EAE; ERK; Gene Repression; Nuclear Receptor; Phosphorylation; Smad7; T Helper Cells; Transcription Target Gene; VDR
Mesh:
Substances:
Year: 2015 PMID: 25809484 PMCID: PMC4424354 DOI: 10.1074/jbc.M114.621839
Source DB: PubMed Journal: J Biol Chem ISSN: 0021-9258 Impact factor: 5.157